rogaratinib + copanlisib

Rogaratinib + copanlisib is an investigational combination of two small molecule targeted therapies developed for the treatment of locally advanced or metastatic solid tumors, primarily those with elevated mRNA expression of at least one FGFR1-4 subtype. Rogaratinib is a potent, selective, small molecule inhibitor of fibroblast growth factor receptors (FGFR 1-4), which inhibits FGFR signaling and thereby downregulates both MAPK and PI3K signaling pathways, showing activity especially in tumors with FGFR upregulation. Copanlisib is a highly selective, intravenous pan-class I PI3K inhibitor with predominant activity against the alpha and delta isoforms of PI3K, FDA-approved for relapsed follicular lymphoma. The combination aims to overcome resistance mechanisms and to provide synergistic anti-tumor effects, particularly in tumors with FGFR pathway activation and PI3KCA mutations. Preclinical and early clinical evidence supports enhanced anti-tumor activity for the combination in certain solid tumor types, including urothelial bladder cancer, hepatocellular carcinoma, and head and neck squamous cell carcinoma, especially in models with specific molecular backgrounds (e.g., FGFR upregulation and PI3KCA mutations)[1][2][3][4].